Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance

Rhea-AI Summary

Lannett Company reported fiscal 2021 Q1 net sales of $126 million, slightly down from $127.3 million a year ago, amidst a challenging market due to the pandemic. The gross profit decreased significantly to 20% of net sales. The company implemented a cost reduction plan aimed to save $15 million annually, alongside launching new products including Levothyroxine Sodium Tablets. Lannett is also paying off Term A Loans to reduce annual expenses by $30 million. The firm maintains its full-year guidance while advancing several promising drug candidates.

Positive

• Cost reduction plan projected to save $15 million annually.
• Launched four new products, including Levothyroxine Sodium Tablets.
• Plans to launch approximately seven more products this fiscal year.
• Paying off Term A Loans will reduce annual interest expense and principal payments by $30 million.

Negative

• Gross profit margin decreased to 20% from 33% year-over-year.
• Net loss of $6.5 million, though an improvement from $12.2 million loss previously.

PHILADELPHIA, Nov. 4, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. 

"We view our fiscal 2021 first quarter net sales of $126 million as a solid achievement, given our current competitive landscape and overall decline of total prescriptions related to the ongoing pandemic," said Tim Crew, chief executive officer of Lannett. "During the quarter, we fully implemented our cost reduction plan that we estimate will lower expenses by approximately $15 million, annually, and launched four new products, including Levothyroxine Sodium Tablets, a meaningful product for us. More recently, we began marketing two additional products, including the exclusive authorized generic of Tirosint^® (Levothyroxine Sodium Capsules), a medication that complements and expands our thyroid deficiency portfolio of products. Our plans include launching approximately seven more products over the balance of the current fiscal year. Based on the aforementioned, we are affirming our previous guidance for the fiscal 2021 full year.

"At the end of this month, we intend to use a portion of our existing cash to pay down, in full, our Term A Loans. This milestone will lower our annual interest expense and principal payments by approximately $30 million, thus improving our financial flexibility. Moreover, our remaining debt is free of financial covenants and the nearest maturity is in November of 2022, two years away.

"We continue to advance a number of drug candidates in our portfolio that we believe have durable value and the potential to be catalysts for significant growth. Our respiratory and biosimilar product candidates with large addressable markets remain on track, and we expect to expand such durable portfolio assets over the course of this fiscal year."

For the fiscal 2021 first quarter on a GAAP basis, net sales were $126.5 million compared with $127.3 million for the first quarter of fiscal 2020. Gross profit was $25.7 million, or 20% of net sales, compared with $42.7 million, or 33% of net sales. The company recorded restructuring expenses of $4.0 million compared with $1.4 million in the prior-year first quarter. Net loss was $6.5 million, or $0.17 per share, compared with $12.2 million, or $0.32 per share, for the first quarter of fiscal 2020.

For the fiscal 2021 first quarter reported on a Non-GAAP basis, net sales were $126.5 million compared with $127.3 million for the first quarter of fiscal 2020. Adjusted gross profit was $34.4 million, or 27% of net sales, compared with $52.6 million, or 41% of net sales, for the prior-year first quarter. Adjusted interest expense decreased to $11.2 million compared with $15.3 million for the first quarter of fiscal 2020. Adjusted net income was $2.2 million, or $0.06 per diluted share, compared with $8.8 million, or $0.22 per diluted share, for the fiscal 2020 first quarter. Adjusted EBITDA for the fiscal 2021 first quarter was $33.2 million.

Conference Call Information and Forward-Looking Statements

Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for its fiscal 2021 first quarter ended September 30, 2020. The conference call will be available to interested parties by dialing 800-447-0521 from the U.S. or Canada, or 847-413-3238 from international locations, passcode 49992942. The call will be broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company's financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

Use of Non-GAAP Financial Measures

This news release contains references to Non-GAAP financial measures, including Adjusted EBITDA, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). Management uses these measures internally for evaluating its operating performance. The Company's management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor's overall understanding of the financial results for the Company's core business. Additionally, it provides a basis for the comparison of the financial results for the Company's core business between current, past and future periods. The company also believes that including Adjusted EBITDA, as defined in the company's existing Credit Agreement, is appropriate to provide additional information to investors to demonstrate the company's ability to comply with financial debt covenants. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. 

Detailed reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included with this release.

Non-GAAP financial measures exclude, among others, the effects of (1) amortization of purchased intangibles and other purchase accounting entries, (2) restructuring expenses, (3) non-cash interest expense, as well as (4) certain other items considered unusual or non-recurring in nature.

Adjusted EBITDA excludes the same adjustments discussed above, as well as additional adjustments permitted under the company's existing Credit Agreement.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications – see financial schedule below for net sales by medical indication. For more information, visit the company's website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statements, including, but not limited to, successfully commercializing recently introduced products, launching and successfully commercializing additional products in fiscal 2021, achieving cost savings from the recently announced restructuring and cost savings plan, the potential material impact of COVID-19 on future financial results, and achieving the financial metrics stated in the company's guidance for fiscal 2021, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including acquired products, and Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.  These forward-looking statements represent the company's judgment as of the date of this news release.  The company disclaims any intent or obligation to update these forward-looking statements.

FINANCIAL SCHEDULES FOLLOW

LANNETT COMPANY, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
				(Unaudited)
				September 30, 2020		June 30, 2020
ASSETS
Current assets:
Cash and cash equivalents				$                               108,774		$                  144,329
Accounts receivable, net				138,796		125,688
Inventories				156,478		142,867
Income taxes receivable				19,703		14,419
Assets held for sale				2,678		2,678
Other current assets				15,787		13,227
Total current assets				442,216		443,208
Property, plant and equipment, net				176,984		179,518
Intangible assets, net				369,146		374,735
Operating lease right-of-use asset				9,085		9,343
Deferred tax assets				120,462		117,890
Other assets				14,027		11,861
TOTAL ASSETS				$                            1,131,920		$               1,136,555
LIABILITIES
Current liabilities:
Accounts payable				$                                  47,539		$                    32,535
Accrued expenses				15,609		14,962
Accrued payroll and payroll-related expenses				9,581		16,304
Rebates payable				43,247		38,175
Royalties payable				18,366		20,863
Restructuring liability				405		27
Current operating lease liabilities				2,018		1,097
Short-term borrowings and current portion of long-term debt				81,314		88,189
Other current liabilities				1,125		2,713
Total current liabilities				219,204		214,865
Long-term debt, net				586,270		592,940
Long-term operating lease liabilities				9,546		9,844
Other liabilities				17,585		16,010
TOTAL LIABILITIES				832,605		833,659
STOCKHOLDERS' EQUITY
Common stock($0.001 par value, 100,000,000 shares authorized; 40,687,784
and 39,963,127 shares issued; 39,393,357 and 38,798,787 shares outstanding at
September 30, 2020 and June 30, 2020, respectively)				41		40
Additional paid-in capital				324,788		321,164
Accumulated deficit				(7,790)		(1,291)
Accumulated other comprehensive loss				(548)		(627)
Treasury stock(1,294,427 and 1,164,340 shares at September 30, 2020 and June 30, 2020, respectively)				(17,176)		(16,390)
Total stockholders' equity				299,315		302,896
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY				$                            1,131,920		$               1,136,555

 

 

LANNETT COMPANY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except share and per share data)
		Three months ended
		September 30,
		2020		2019
Net sales		$             126,479		$         127,342
Cost of sales		92,187		77,656
Amortization of intangibles		8,589		7,028
Gross profit		25,703		42,658
Operating expenses:
Research and development expenses		6,539		8,940
Selling, general and administrative expenses		15,136		21,308
Restructuring expenses		4,043		1,388
Asset impairment charges		-		1,618
Total operating expenses		25,718		33,254
Operating income (loss)		(15)		9,404
Other income (loss):
Loss on extinguishment of debt		-		(2,145)
Investment income		45		729
Interest expense		(14,486)		(19,292)
Other		(23)		934
Total other loss		(14,464)		(19,774)
Loss before income tax		(14,479)		(10,370)
Income tax expense (benefit)		(7,980)		1,787
Net loss		$                (6,499)		$         (12,157)
Loss per common share:
Basic		$                  (0.17)		$             (0.32)
Diluted (1)		$                  (0.17)		$             (0.32)
Weighted average common shares outstanding:
Basic		39,070,982		38,309,267
Diluted (1)		39,070,982		38,309,267

(1) Effective with the 4.5% Senior Convertible Note issued on September 27, 2019, the diluted earnings per share was calculated based on the "if-converted" method.

 

 

LANNETT COMPANY, INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)
(In thousands, except percentages, share and per share data)
Three months ended September 30, 2020
	Net sales	Cost of sales	Amortization of intangibles	Gross Profit	Gross Margin %	R&D expenses	SG&A expenses	Restructuring expenses	Operating income (loss)	Other income (loss)	Income (loss) before income tax	Income tax expense (benefit)	Net income (loss)	Diluted earnings (loss) per share (h)
GAAP Reported	$126,479	$     92,187	$        8,589	$ 25,703	20%	$     6,539	$      15,136	$        4,043	$              (15)	$ (14,464)	$   (14,479)	$ (7,980)	$    (6,499)	$         (0.17)
Adjustments:
Amortization of intangibles (a)	-	-	(8,589)	8,589		-	-	-	8,589	-	8,589	-	8,589
Cody API business (b)	-	(74)	-	74		(2)	(427)	-	503	-	503	-	503
Depreciation on capitalized software costs (c)	-	-	-	-		-	(1,051)	-	1,051	-	1,051	-	1,051
Restructuring expenses (d)	-	-	-	-		-	-	(4,043)	4,043	-	4,043	-	4,043
Non-cash interest (e)	-	-	-	-		-	-	-	-	3,277	3,277	-	3,277
Other (f)	-	-	-	-		-	(951)	-	951	-	951	-	951
Tax adjustments (g)	-	-	-	-		-	-	-	-	-	-	9,669	(9,669)
Non-GAAP Adjusted	$  126,479	$       92,113	$              -	$   34,366	27%	$       6,537	$        12,707	$              -	$          15,122	$   (11,187)	$        3,935	$    1,689	$       2,246	$            0.06
(a)	To exclude amortization of purchased intangible assets primarily related to the acquisition of KUPI
(b)	To exclude the operating results of the ceased Cody API business
(c)	To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition
(d)	To exclude expenses associated with the 2020 Restructuring Plan
(e)	To exclude non-cash interest expense associated with debt issuance costs
(f)	To primarily exclude the reimbursement of legal costs associated with a distribution agreement
(g)	To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates
(h)	The weighted average share number for the three months ended September 30, 2020 is 39,070,982 for GAAP and 40,717,506 for non-GAAP earnings (loss) per share calculations

 

 

LANNETT COMPANY, INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)
(In thousands, except percentages, share and per share data)
Three months ended September 30, 2019
	Net sales	Cost of sales	Amortization of intangibles	Gross Profit	Gross Margin %	R&D expense	SG&A expense	Restructuring expenses	Asset impairment charges	Operating income	Other income (loss)	Income (loss) before income tax	Income tax expense	Net income (loss)	Diluted earnings (loss) per share (k)
GAAP Reported	$        127,342	$           77,656	$             7,028	$            42,658	33%	$             8,940	$           21,308	$             1,388	1,618	$             9,404	$         (19,774)	$         (10,370)	$            1,787	$          (12,157)	$             (0.32)
Adjustments:
Amortization of intangibles (a)	-	-	(7,028)	7,028		-	-	-	-	7,028	-	7,028	-	7,028
Cody API business (b)	-	(1,722)	-	1,722		(420)	(214)	-		2,356	-	2,356	-	2,356
Depreciation on capitalized software costs (c)	-	-	-	-		-	(1,058)	-	-	1,058	-	1,058	-	1,058
Decommissioning of Philadelphia sites (d)	-	(989)	-	989		-	-	-	-	989	-	989	-	989
Restructuring expenses (e)	-	-	-	-		-	-	(1,388)	-	1,388	-	1,388	-	1,388
Asset impairment charges (f)	-	-	-	-		-	-	-	(1,618)	1,618	-	1,618	-	1,618
Non-cash interest (g)	-	-	-	-		-	-	-	-	-	4,008	4,008	-	4,008
Loss on extinguishment of debt (h)	-	-	-	-		-	-	-	-	-	2,145	2,145	-	2,145
Other (i)	-	(208)	-	208		-	(2,090)	-	-	2,298	(966)	1,332	-	1,332
Tax adjustments (j)	-	-	-	-		-	-	-	-	-	-	-	999	(999)
Non-GAAP Adjusted	$           127,342	$             74,737	$                   -	$             52,605	41%	$               8,520	$            17,946	$                    -	$                     -	$            26,139	$           (14,587)	$             11,552	$               2,786	$               8,766	$                 0.22
(a)	To exclude amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc.
(b)	To exclude the operating results of the ceased Cody API business
(c)	To exclude depreciation on previously capitalized software integration costs associated with the KUPI acquisition
(d)	To exclude the costs related to the decommissioning and shutdown of the Philadelphia manufacturing and distribution sites
(e)	To exclude expenses associated with the Cody API Restructuring Plan
(f)	To exclude impairment charges primarily associated with an operating lease right-of-use asset
(g)	To exclude non-cash interest expense associated with debt issuance costs
(h)	To exclude the loss on extinguishment of debt primarily related to the partial repayment of outstanding Term Loan A balance
(i)	To primarily exclude accrued separation costs related to the Company's former Chief Financial Officer as well as gains on sales of assets previously held for sale
(j)	To exclude the tax effect of the pre-tax adjustments included above at applicable tax rates
(k)	The weighted average share number for the three months ended September 30, 2019 is 38,309,267 for GAAP and 40,653,053 for the non-GAAP earnings (loss) per share calculations. As a result of the 4.5% Senior Convertible Note issued on September 27, 2019, the diluted earnings per share was calculated based on the "if-converted" method.

 

 

LANNETT COMPANY, INC.
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (UNAUDITED)
($ in thousands)
		Three months ended
		September 30, 2020
Net loss		$                                 (6,499)
Interest expense		14,486
Depreciation and amortization		14,342
Income tax benefit		(7,980)
EBITDA		14,349
Share-based compensation		3,342
Inventory write-down		2,605
Investment income		(45)
Other non-operating loss		23
Restructuring expenses		4,043
Restructuring payments		(3,666)
Unrealized cost savings (a)		11,250
Other(b)		1,313
Adjusted EBITDA (Non-GAAP)		$                                33,214

(a)	To include the remaining cost savings expected to be realized as a result of the 2020 Restructuring Plan
(b)	To primarily exclude the reimbursement of legal costs associated with a distribution agreement, as well as the operating results of the ceased Cody API business

 

 

LANNETT COMPANY, INC.
NET SALES BY MEDICAL INDICATION
	Three months ended
($ in thousands)	September 30,
Medical Indication	2020		2019
Analgesic	$             3,120		$             1,884
Anti-Psychosis	13,028		28,034
Cardiovascular	19,714		21,606
Central Nervous System	22,525		19,257
Endocrinology	3,233		-
Gastrointestinal	17,100		16,962
Infectious Disease	21,932		11,895
Migraine	9,690		9,143
Respiratory/Allergy/Cough/Cold	1,426		2,707
Urinary	1,458		435
Other	7,634		9,861
Contract Manufacturing revenue	5,619		5,558
Net Sales	$          126,479		$          127,342

 

Contact:	Robert Jaffe
	Robert Jaffe Co., LLC
	(424) 288-4098

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lannett-announces-fiscal-2021-first-quarter-financial-results-affirms-guidance-301166643.html

SOURCE Lannett Company, Inc.